{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:13:27Z","timestamp":1792145607760,"version":"4.4.0"},"reference-count":156,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Epidermolysis bullosa acquisita (EBA) is a rare chronic autoimmune subepidermal blistering disease of the skin and mucous membranes, usually beginning in adulthood. EBA is induced by autoantibodies to type VII collagen, a major component of anchoring fibrils in the dermal\u2013epidermal junction (DEJ). The binding of autoantibodies to type-VII collagen subsequently leads to the detachment of the epidermis and the formation of mucocutaneous blisters. EBA has two major clinical subtypes: the mechanobullous and inflammatory variants. The classic mechanobullous variant presentation consists of skin fragility, bullae with minimal clinical or histological inflammation, erosions in acral distribution that heal with scarring, and milia formation. The inflammatory variant is challenging to differentiate from other autoimmune bullous diseases, most commonly bullous pemphigoid (BP) but also mucous membrane pemphigoid (MMP), Brunsting\u2013Perry pemphigoid, and linear IgA dermatosis. Due to its recalcitrance conventional treatment of epidermolysis bullosa acquisita is shown to be demanding. Here we discuss novel therapeutic strategies that have emerged and which could potentially improve the quality of life in patients with EBA.<\/jats:p>","DOI":"10.3390\/jcm12031139","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T02:29:03Z","timestamp":1675218543000},"page":"1139","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Epidermolysis Bullosa Acquisita\u2014Current and Emerging Treatments"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-3361","authenticated-orcid":false,"given":"De\u0161a","family":"Te\u0161anovi\u0107 Perkovi\u0107","sequence":"first","affiliation":[{"name":"Special Hospital Agram, Trnjanska Cesta 108, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zrinka","family":"Bukvi\u0107 Mokos","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, School of Medicine, University Hospital Centre Zagreb, University of Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Marinovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, School of Medicine, University Hospital Centre Zagreb, University of Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2133.2011.10346.x","article-title":"The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy","volume":"165","author":"Buijsrogge","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2340\/00015555-1065","article-title":"Epidermolysis Bullosa Acquisita: A Retrospective Clinical Analysis of 30 Cases","volume":"91","author":"Kim","year":"2011","journal-title":"Acta Derm. Venereol."},{"key":"ref_3","first-page":"111","article-title":"Review and update of epidermolysis bullosa acquisita","volume":"7","author":"Woodley","year":"1988","journal-title":"Semin. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/01.md.0000231954.08350.52","article-title":"A Prospective Study of Upper Aerodigestive Tract Manifestations of Mucous Membrane Pemphigoid","volume":"85","author":"Alexandre","year":"2006","journal-title":"Medicine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/JID.2015.356","article-title":"Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options","volume":"136","author":"Kasperkiewicz","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI113373","article-title":"Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen","volume":"81","author":"Woodley","year":"1988","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2172-13-16","article-title":"Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases","volume":"13","author":"Licarete","year":"2012","journal-title":"BMC Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and Age Distribution of Pemphigus and Pemphigoid Diseases in Germany","volume":"136","author":"Recke","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-018-0896-1","article-title":"Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients","volume":"13","author":"Iwata","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_10","first-page":"434","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/ddg.13081","article-title":"Incidence of autoimmune bullous diseases in Serbia: A 20-year retrospective study","volume":"14","author":"Medenica","year":"2016","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/1744666X.2016.1196136","article-title":"Clinical and immunological studies for 105 Japanese seropositive patients of epidermolysis bullosa acquisita examined at Kurume University","volume":"12","author":"Hashimoto","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_14","first-page":"187","article-title":"Prevalences of subacute cutaneous lupus erythematosus and Epidermolysis bullosa acquisita among Korean\/Oriental populations","volume":"197","author":"Lee","year":"1998","journal-title":"Dermatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"812029","DOI":"10.1155\/2013\/812029","article-title":"Clinical Presentation, Pathogenesis, Diagnosis, and Treatment of Epidermolysis Bullosa Acquisita","volume":"2013","author":"Ludwig","year":"2013","journal-title":"ISRN Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1346-8138.2009.00799.x","article-title":"Epidermolysis bullosa acquisita: What\u2019s new?","volume":"37","author":"Ishii","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/08916934.2011.606450","article-title":"Epidermolysis bullosa acquisita: Autoimmunity to anchoring fibril collagen","volume":"45","author":"Chen","year":"2011","journal-title":"Autoimmunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/jid.2014.547","article-title":"Malignancies in Pemphigus and Pemphigoid Diseases","volume":"135","author":"Schulze","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1067\/mjd.2002.107774","article-title":"Drug-induced epidermolysis bullosa acquisita with antibodies to type VII collagen","volume":"46","author":"Delbaldo","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2133.2000.03368.x","article-title":"Epidermolysis bullosa acquisita with ultraviolet radiation sensitivity","volume":"142","author":"Jappe","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1346-8138.2010.00810.x","article-title":"Metal sensitization precipitates skin blistering in epidermolysis bullosa acquisita","volume":"37","author":"Baican","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1365-2133.1998.02081.x","article-title":"Drug-induced linear IgA disease with antibodies to collagen VII","volume":"138","author":"Wakelin","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archderm.1971.04000130003001","article-title":"Epidermolysis bullosa acquisita. Report of three cases and review of all published cases","volume":"103","author":"Roenigk","year":"1971","journal-title":"Arch. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0190-9622(84)80459-4","article-title":"Epidermolysis bullosa acquisita\u2014A pemphigoid-like disease","volume":"11","author":"Gammon","year":"1984","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archderm.1991.01680030111016","article-title":"Acquired epidermolysis bullosa with the clinical feature of Brunsting-Perry cicatricial bullous pemphigoid","volume":"127","author":"Kurzhals","year":"1991","journal-title":"Arch. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0190-9622(94)70252-7","article-title":"Linear IgA bullous dermatosis with autoantibodies to a 290 kd antigen of anchoring fibrils","volume":"31","author":"Zambruno","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2133.1979.tb00030.x","article-title":"Epidermolysis bullosa acquisita\u2013a sign of cicatricial pemphigoid?","volume":"101","author":"Dahl","year":"1979","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/1744666X.2016.1221343","article-title":"Clinical features and diagnosis of epidermolysis bullosa acquisita","volume":"13","author":"Vorobyev","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fmed.2018.00362","article-title":"Epidermolysis Bullosa Acquisita: The 2019 Update","volume":"5","author":"Koga","year":"2019","journal-title":"Front. Med."},{"key":"ref_30","first-page":"217","article-title":"Clinical features and practical diagnosis of bullous pemphigoid","volume":"32","author":"Schmidt","year":"2012","journal-title":"Immunol. Allergy Clin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0190-9622(82)80319-8","article-title":"Epidermolysis bullosa acquisita presenting as an inflammatory bullous disease","volume":"7","author":"Gammon","year":"1982","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: Definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/archderm.135.8.954","article-title":"Mucosal Morbidity in Patients With Epidermolysis Bullosa Acquisita","volume":"135","author":"Luke","year":"1999","journal-title":"Arch. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/archopht.124.11.1615","article-title":"Chronic Cicatrizing Conjunctivitis in a Patient With Epidermolysis Bullosa Acquisita","volume":"124","author":"Letko","year":"2006","journal-title":"Arch. Ophthalmol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0190-9622(87)70057-7","article-title":"Severe ocular involvement in a patient with epidermolysis bullosa acquisita","volume":"16","author":"Lang","year":"1987","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1111\/1523-1747.ep12275505","article-title":"Epidermolysis Bullosa Acquisita of the Immunopathological Type (Dermolytic Pemphigoid)","volume":"85","author":"Briggaman","year":"1985","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2230.2010.03845.x","article-title":"Clinical and immunopathological evaluation of epidermolysis bullosa acquisita","volume":"36","author":"Delgado","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2340\/00015555-1163","article-title":"A Case of Epidermolysis Bullosa Acquisita Associated with Laryngeal Stenosis","volume":"92","author":"Kiniwa","year":"2012","journal-title":"Acta Dermato-Venereologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/ced.12009","article-title":"Beware the blistering patient with dysphonia","volume":"38","author":"Benton","year":"2013","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/j.annder.2014.09.091","article-title":"Pemphigoide des muqueuses avec st\u00e9nose laryng\u00e9e ou trach\u00e9ale","volume":"141","author":"Poirier","year":"2014","journal-title":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1067\/mjd.2002.125079","article-title":"IgA-mediated epidermolysis bullosa acquisita: Two cases and review of the literature","volume":"47","author":"Vodegel","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.1365-2133.1999.03163.x","article-title":"Ocular involvement in IgA-epidermolysis bullosa acquisita","volume":"141","author":"Bauer","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2133.1996.tb07624.x","article-title":"A case of linear IgA bullous dermatosis with IgA anti-type VII collagen autoantibodies","volume":"134","author":"Hashimoto","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/archderm.1957.01550160015002","article-title":"Benign pemphigoid; a report of seven cases with chronic, scarring, herpetiform plaques about the head and neck","volume":"75","author":"Brunsting","year":"1957","journal-title":"AMA Arch. Derm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clindermatol.2011.03.011","article-title":"Epidermolysis bullosa acquisita","volume":"30","author":"Gupta","year":"2012","journal-title":"Clin. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study","volume":"129","author":"Joly","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for mucous membrane pemphigoid: Recommendations of an international panel of experts","volume":"72","author":"Murrell","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bjd.16138","article-title":"International Bullous Diseases Group: Consensus on diagnostic criteria for epidermolysis bullosa acquisita","volume":"179","author":"Caux","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_50","first-page":"713","article-title":"S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Schmidt","year":"2015","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2133.2004.06006.x","article-title":"U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases","volume":"151","author":"Vodegel","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjd.12308","article-title":"The n- vs. u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis","volume":"169","author":"Terra","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2133.2011.10474.x","article-title":"Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: Immunopathological findings and clinical experience in 10 Dutch patients","volume":"165","author":"Terra","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/1523-1747.ep12543517","article-title":"Localization of Basement Membrane Components After Dermal-Epidermal Junction Separation","volume":"81","author":"Woodley","year":"1983","journal-title":"J. Investig. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/1523-1747.ep12259692","article-title":"Differentiatinganti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin","volume":"82","author":"Gammon","year":"1984","journal-title":"J. Investig. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2133.1987.tb04927.x","article-title":"Localization of bullous pem-phigoid antibody\u2013an indirect immunofluorescence study of 228 cases using a split-skin technique","volume":"117","author":"Logan","year":"1987","journal-title":"Br. J. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0190-9622(96)90604-0","article-title":"Reactivity of autoantibodies from patients with defined subepidermal bullous diseases against 1 mol\/L salt-split skin: Specificity, sensitivity, and practical considerations","volume":"35","author":"Lazarova","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_58","first-page":"1","article-title":"Immunobullous diseases","volume":"Volume 50","author":"Griffith","year":"2016","journal-title":"Rook\u2019s Textbook of Dermatology, Part 3, Chapter 50"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jaad.2014.02.036","article-title":"Anti-p200 pemphigoid","volume":"71","author":"Goletz","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/43.7.7608519","article-title":"Fluorescence overlay antigen mapping of the epidermal basement membrane zone: III. Topographic staining and effective resolution","volume":"43","author":"Bruins","year":"1995","journal-title":"J. Histochem. Cytochem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/archderm.1996.03890260053008","article-title":"Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping","volume":"132","author":"Bruins","year":"1996","journal-title":"Arch. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/archderm.139.8.1007","article-title":"A practical technique for differentiation of subepidermal bullous diseases: Localization of in vivo-bound IgG by laser scanning confocal microscopy","volume":"139","author":"Wozniak","year":"2003","journal-title":"Arch. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/archderm.136.2.227","article-title":"Inflammatory Variant of Epidermolysis Bullosa Acquisita With IgG Autoantibodies Against Type VII Collagen and Laminin \u03b13","volume":"136","author":"Jonkman","year":"2000","journal-title":"Arch. Dermatol."},{"key":"ref_64","first-page":"83","article-title":"The use of skin substrates deficient in basement membrane molecules for the diagnosis of subepidermal autoimmune bullous disease","volume":"8","author":"Vodegel","year":"1998","journal-title":"Eur. J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Murrell, D. (2015). Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer.","DOI":"10.1007\/978-3-662-45698-9"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jdermsci.2011.03.003","article-title":"Development of NC1 and NC2 domains of Type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients","volume":"62","author":"Saleh","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jaad.2016.01.005","article-title":"Comparison of 3 type VII collagen (C7) assays for serologic diagnosis of epidermolysis bullosa acquisita (EBA)","volume":"74","author":"Seta","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2016.11.002","article-title":"Prospective studies on the routine use of a novel multivariant enzyme-linked immunosorbent assay for the diagnosis of autoimmune bullous diseases","volume":"76","author":"Johannsen","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2011.12.032","article-title":"Sensitive and specificassays for routine serological diagnosis of epidermolysis bullosaacquisita","volume":"68","author":"Komorowski","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00403-016-1632-0","article-title":"The use of Biochip immunofluorescence microscopy for the serological diagnosis of epidermolysis bullosa acquisita","volume":"308","author":"Marzano","year":"2016","journal-title":"Arch. Dermatol. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1172\/JCI116774","article-title":"Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa","volume":"92","author":"Lapiere","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1046\/j.1523-1747.2002.01772.x","article-title":"The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn\u2019s disease have autoantibodies to type VII collagen","volume":"118","author":"Chen","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archderm.135.5.569","article-title":"Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen","volume":"135","author":"Chan","year":"1999","journal-title":"Arch. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0190-9622(86)70181-3","article-title":"Bullous systemic lupus erythematosus: An unusual clinical course and detectable circulating autoantibodies to the epidermolysis bullosa acquisita antigen","volume":"15","author":"Barton","year":"1986","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjd.12300","article-title":"Low sensitivity of typeVII collagen enzyme-linked immunosorbent assay in epidermolysisbullosa acquisita: Serration pattern analysis on skin biopsy isrequired for diagnosis","volume":"169","author":"Terra","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_76","first-page":"702","article-title":"Epidermolysis bullosa acquisita","volume":"Volume 1\u20132","author":"Fitzpatrick","year":"1998","journal-title":"Dermatology in General Medicine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0190-9622(97)80411-2","article-title":"Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita","volume":"36","author":"Kofler","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(86)70103-5","article-title":"Epidermolysis bullosa acquisita: Clinical response to plasma exchange therapy and circulating anti-BMZ antibody titre","volume":"14","author":"Furue","year":"1986","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2133.1997.5771549.x","article-title":"Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy","volume":"136","author":"Gordon","year":"1997","journal-title":"Br. J. Dermatol."},{"key":"ref_80","first-page":"612","article-title":"Resistant acquired bullous epidermolysis with severe ocular involvement: The success of extracorporeal photochemotherapy","volume":"126","author":"Camara","year":"1999","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s001060050412","article-title":"Manifestation of epidermolysis bullosa acquisita (EBA) in the ENT area","volume":"47","author":"Bloching","year":"1999","journal-title":"HNO"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaad.2008.12.020","article-title":"A case of epidermolysis bullosa acquisita with clinical features of Brunsting-Perry pemphigoid showing an excellent response to colchicine","volume":"61","author":"Tanaka","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/1346-8138.13395","article-title":"Oral colchicine monotherapy for epidermolysis bullosa acquisita: Mechanism of action and efficacy","volume":"43","author":"Adachi","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00375841","article-title":"Epidermolysis bullosa acquisita\u2013successful treatment with colchicine","volume":"286","author":"Megahed","year":"1994","journal-title":"Arch. Dermatol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"bcr2015210210","DOI":"10.1136\/bcr-2015-210210","article-title":"Epidermolysis bullosa acquisita in a 17- year-old boy with Crohn\u2019s disease","volume":"2015","author":"Russo","year":"2015","journal-title":"BMJ Case Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/14656566.2011.549127","article-title":"Current concepts in the treatment of epidermolysis bullosa acquisita","volume":"12","author":"Ahmed","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/120347540100500505","article-title":"Epidermolysis bullosa acquisita responsive to dapsone therapy","volume":"5","author":"Hughes","year":"2001","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulfones in dermatology: Overview and update","volume":"45","author":"Zhu","year":"2001","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid","volume":"161","author":"Ahmed","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","article-title":"The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review","volume":"50","author":"Fraser","year":"2002","journal-title":"Gut"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2010.02.062","article-title":"The use of cyclosporine in dermatology: Part II","volume":"63","author":"Ryan","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1191\/0961203305LU2109OA","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2010.91","article-title":"Treating Pemphigus Vulgaris with Prednisone and Mycophenolate Mofetil: A Multicenter, Randomized, Placebo-Controlled Trial","volume":"130","author":"Beissert","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jaad.2005.07.009","article-title":"Childhood IgA-mediated epidermolysis bullosa acquisita responding to mycophenolate mofetil as a corticosteroid-sparing agent","volume":"54","author":"Tran","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jdcr.2015.07.007","article-title":"Mycophenolate mofetil (MMF) in the treatment of epidermolysis bullosa acquisita (EBA) long-term follow-up","volume":"1","author":"Sami","year":"2015","journal-title":"JAAD Case Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1468-3083.2011.04205.x","article-title":"Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: Clinical outcome and post-treatment long-term follow-up","volume":"26","author":"Ahmed","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in Severe Pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/jdv.12096","article-title":"Epidermolysis bullosa acquisita","volume":"27","author":"Kim","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e12726","DOI":"10.1111\/dth.12726","article-title":"The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature","volume":"31","author":"Bevans","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/archderm.143.2.192","article-title":"Clinical Response of Severe Mechanobullous Epidermolysis Bullosa Acquisita to Combined Treatment With Immunoadsorption and Rituximab (Anti-CD20 Monoclonal Antibodies)","volume":"143","author":"Niedermeier","year":"2007","journal-title":"Arch. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/09546634.2016.1179711","article-title":"Long-term results of rituximab\u2013intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy","volume":"28","author":"Oktem","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e243432","DOI":"10.1136\/bcr-2021-243432","article-title":"Epidermolysis bullosa acquisita treated with rituximab","volume":"14","author":"Mendes","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1046\/j.1365-2133.2003.05302.x","article-title":"Protein A immunoadsorption: A novel and effective adjuvant treatment of severe pemphigus","volume":"148","author":"Schmidt","year":"2003","journal-title":"Br. J. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/jdv.12175","article-title":"Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: A protocol without initial high dose or pulse steroid medication","volume":"28","author":"Kolesnik","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_111","first-page":"289","article-title":"Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: Successful treatment with rituximab and protein A immunoapheresis","volume":"11","author":"Kubisch","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12016-007-0027-6","article-title":"Autoimmunity to Type VII Collagen: Epidermolysis Bullosa Acquisita","volume":"33","author":"Woodley","year":"2007","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1684\/ejd.2012.1840","article-title":"Long-term efficacy of extracorporeal photochemotherapy in a patient with refractory epidermolysis bullosa acquisita","volume":"22","author":"Baroudjian","year":"2012","journal-title":"Eur. J. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2133.1995.tb02680.x","article-title":"Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy","volume":"133","author":"Miller","year":"1995","journal-title":"Br. J. Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/clim.2001.5113","article-title":"Treatment of Epidermolysis Bullosa Acquisita with the Humanized Anti-Tac mAb Daclizumab","volume":"101","author":"Egan","year":"2001","journal-title":"Clin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2340\/00015555-1804","article-title":"Inflammatory Epidermolysis Bullosa Acquisita Effectively Treated with Minocycline","volume":"94","author":"Kawase","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/1523-1747.ep12470317","article-title":"Increased Frequency of HLA-DR2 in Patients with Autoantibodies to Epidermolysis Bullosa Acquisita Antigen: Evidence that the Expression of Autoimmunity to Type VII Collagen Is HLA Class II Allele Associated","volume":"91","author":"Gammon","year":"1988","journal-title":"J. Investig. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1038\/jid.2011.231","article-title":"Black Patients of African Descent and HLA-DRB1*15:03 Frequency Overrepresented in Epidermolysis Bullosa Acquisita","volume":"131","author":"Zumelzu","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.4049\/jimmunol.1300310","article-title":"B Cells, Dendritic Cells, and Macrophages Are Required To Induce an Autoreactive CD4 Helper T Cell Response in Experimental Epidermolysis Bullosa Acquisita","volume":"191","author":"Iwata","year":"2013","journal-title":"J. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI200521386","article-title":"Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen","volume":"115","author":"Sitaru","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2009.12.010","article-title":"T and B cells target identical regions of the non-collagenous domain 1 of type VII collagen in epidermolysis bullosa acquisita","volume":"135","author":"Dahler","year":"2010","journal-title":"Clin. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.4049\/jimmunol.0901412","article-title":"T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita","volume":"184","author":"Sitaru","year":"2010","journal-title":"J. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.4049\/jimmunol.1100796","article-title":"Complement-Fixing Anti-Type VII Collagen Antibodies Are Induced in Th1-Polarized Lymph Nodes of Epidermolysis Bullosa Acquisita-Susceptible Mice","volume":"187","author":"Hammers","year":"2011","journal-title":"J. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2249.2006.03115.x","article-title":"Autoimmunity to type VII collagen in SKH1 mice is independent of regulatory T cells","volume":"145","author":"Chen","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4049\/jimmunol.1301556","article-title":"GM-CSF Modulates Autoantibody Production and Skin Blistering in Experimental Epidermolysis Bullosa Acquisita","volume":"192","author":"Samavedam","year":"2014","journal-title":"J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Tiburzy, B., Szyska, M., Iwata, H., Chrobok, N., Kulkarni, U., Hirose, M., Ludwig, R.J., Kalies, K., Westermann, J., and Wong, D. (2013). Persistent Autoantibody-Production by Intermediates between Short-and Long-Lived Plasma Cells in Inflamed Lymph Nodes of Experimental Epidermolysis Bullosa Acquisita. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083631"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders","volume":"34","author":"Schmidt","year":"2007","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1365-2133.2010.09680.x","article-title":"Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita","volume":"162","author":"Kasperkiewicz","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-3-319-07911-0_12","article-title":"FcRn: From Molecular Interactions to Regulation of IgG Pharmacokinetics and Functions","volume":"382","author":"Challa","year":"2014","journal-title":"Fc Recept."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2133.2007.08388.x","article-title":"Binding of avian IgY to type VII collagen does not activate complement and leucocytes and fails to induce subepidermal blistering in mice","volume":"158","author":"Sesarman","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/path.2157","article-title":"NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage","volume":"212","author":"Chiriac","year":"2007","journal-title":"J. Pathol."},{"key":"ref_132","first-page":"2","article-title":"The allosteric CXCR1\/2 inhibitor DF2156A improves experimental epidermolysis bullosa acquisita","volume":"3","author":"Hirose","year":"2013","journal-title":"J. Genet. Syndr. Gene Ther. S"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.4049\/jimmunol.1402688","article-title":"Caspase-1\u2013Independent IL-1 Release Mediates Blister Formation in Autoantibody-Induced Tissue Injury through Modulation of Endothelial Adhesion Molecules","volume":"194","author":"Sadeghi","year":"2015","journal-title":"J. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2012.08.002","article-title":"Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction","volume":"40","author":"Samavedam","year":"2013","journal-title":"J. Autoimmun."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/path.4023","article-title":"Genetic identification and functional validation of FcgRIV as key molecule in autoantibody-induced tissue injury","volume":"228","author":"Kasperkiewicz","year":"2012","journal-title":"J. Pathol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/jid.2013.91","article-title":"Methylprednisolone Blocks Autoantibody-Induced Tissue Damage in Experimental Models of Bullous Pemphigoid and Epidermolysis Bullosa Acquisita through Inhibition of Neutrophil Activation","volume":"133","author":"Hellberg","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"ra23","DOI":"10.1126\/scisignal.2001617","article-title":"PI3Kb plays a critical role in neutrophil activation by immune complexes","volume":"4","author":"Kulkarni","year":"2011","journal-title":"Sci. Signal."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4556","article-title":"The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita","volume":"237","author":"Sadeghi","year":"2015","journal-title":"J. Pathol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.biocel.2007.04.011","article-title":"Flightless I: An actin-remodelling protein and an important negative regulator of wound repair","volume":"40","author":"Kopecki","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/path.2973","article-title":"Overexpression of the Flii gene increases dermal-epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita","volume":"225","author":"Kopecki","year":"2011","journal-title":"J. Pathol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/jid.2012.457","article-title":"Topically Applied Flightless I Neutralizing Antibodies Improve Healing of Blistered Skin in a Murine Model of Epidermolysis Bullosa Acquisita","volume":"133","author":"Kopecki","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/exd.12011","article-title":"Evidence for pathogenicity of autoreactive T cells in autoimmune bullous diseases shown by animal disease models","volume":"21","author":"Ujiie","year":"2012","journal-title":"Exp. Dermatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1182\/blood-2010-10-314609","article-title":"Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: Evidence that nonmalignant plasma cells are not therapeutic targets","volume":"117","author":"Kasperkiewicz","year":"2011","journal-title":"Blood"},{"key":"ref_144","first-page":"907","article-title":"Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review)","volume":"46","author":"Mojzis","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/mi.2012.134","article-title":"Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function","volume":"6","author":"Collins","year":"2013","journal-title":"Mucosal. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/MCB.05155-11","article-title":"Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(\u00fe) T-regulatory cells","volume":"31","author":"Wang","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/exd.12476","article-title":"Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses","volume":"23","author":"Tukaj","year":"2014","journal-title":"Exp. Dermatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-9255-11-10","article-title":"Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations","volume":"11","author":"Tukaj","year":"2014","journal-title":"J. Inflamm."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s12192-014-0513-8","article-title":"Hsp90 blockade modulates bullous pemphigoid IgG-induced ILe8 production by keratinocytes","volume":"19","author":"Tukaj","year":"2014","journal-title":"Cell Stress Chaperones."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/exd.12680","article-title":"Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita","volume":"24","author":"Tukaj","year":"2015","journal-title":"Exp. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/exd.12760","article-title":"Heat shock protein 90: A pathophysiological factor and novel treatment target in autoimmune bullous skin diseases","volume":"24","author":"Tukaj","year":"2015","journal-title":"Exp. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/eji.201344230","article-title":"Broad requirement for terminal sialic acid residues and FcgRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo","volume":"44","author":"Schwab","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"E1297","DOI":"10.1073\/pnas.1422481112","article-title":"Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity","volume":"112","author":"Washburn","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/jid.2014.451","article-title":"Recombinant Soluble CD32 Suppresses Disease Progression in Experimental Epidermolysis Bullosa Acquisita","volume":"135","author":"Iwata","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/bph.14986","article-title":"Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice","volume":"177","author":"Kasprick","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41467-020-20604-3","article-title":"Granzyme B inhibition reduces disease severity in autoimmune blistering diseases","volume":"12","author":"Hiroyasu","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/1139\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:20:42Z","timestamp":1760120442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/1139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":156,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jcm12031139"],"URL":"https:\/\/doi.org\/10.3390\/jcm12031139","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}